A5072950514- Inflammatory Bowel Disease
- Microscopic Colitis
- Gastrointestinal motility and disorders
- Clostridium difficile and Clostridium perfringens research
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Gut microbiota and health
- Immunodeficiency and Autoimmune Disorders
- Digestive system and related health
- Clinical Nutrition and Gastroenterology
- Helicobacter pylori-related gastroenterology studies
- Organ Transplantation Techniques and Outcomes
- Diverticular Disease and Complications
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Pulmonary Hypertension Research and Treatments
- Gastrointestinal disorders and treatments
- Complementary and Alternative Medicine Studies
- Drug Transport and Resistance Mechanisms
- Pancreatitis Pathology and Treatment
- Celiac Disease Research and Management
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Dermatological and Skeletal Disorders
- Microbial Metabolites in Food Biotechnology
- Immune cells in cancer
Ghent University Hospital
2015-2025
Vlaamse Vereniging voor Obstetrie en Gynaecolo
2021-2025
Ghent University
2011-2024
VIB-UGent Center for Inflammation Research
2024
KU Leuven
2014
The promising results seen in studies of secondary bile acids experimental colitis suggest that they may represent an attractive and safe class drugs for the treatment inflammatory bowel diseases (IBD). However, exact mechanism by which acid therapy confers protection from colitogenesis is currently unknown. Since gut microbiota plays a crucial role pathogenesis IBD, exogenous administration affect community structure microbiota, we examined impact ursodeoxycholic (UDCA) its taurine or...
Abstract Background and Aims No consensus exists on optimal strategy to prevent postoperative recurrence [POR] after ileocaecal resection [ICR] for Crohn’s disease [CD]. We compared early medical prophylaxis versus expectant management with treatment driven by findings at elective endoscopy 6–12 months ICR. Methods A retrospective, multicentric, observational study was performed. CD patients undergoing first ICR were assigned Cohort 1 if a biologic or immunomodulator [re]started...
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of current study was to assess safety effectiveness both an real-life population. Methods: A multicentric retrospective performed IBD patients who started or between 2010 2020. Clinical endoscopic remission rates (serious) adverse events (AE) were assessed. Results: total 911 included, with 171 (19%) aged above 60 (111 VDZ, UST). Elderly treated had increased risk...
Abstract Background While genetics has been shown to direct wound healing responses toward or progressive fibrosis in liver and lung disease, attempts identify genes involved fibrostenotic Crohn’s disease (CD) have not successful. This knowledge gap stems partly from the challenge uniformly define fibrostenosis, for which golden standard currently is surgery. We aimed investigate genetic basis of CD by conducting a case-control association study well-defined cohort, assessing presence...
Abstract Background Histological remission is an aspirational therapeutic target in Ulcerative Colitis (UC) associated with lower relapse rates.1Ustekinumab (UST), a monoclonal antibody against the p40 subunit of interleukin (IL) 12 and 23 has shown UNIFI trials to be effective safe patients moderate-to-severe UC. However, real-life data on histological rates are sparse. The aim study was assess response UST UC across Belgian hospitals. Methods In this multicentric, retrospective...
Abstract Background The therapeutic options for Inflammatory Bowel Disease (IBD) have expanded with the introduction of JAK inhibitors. However, real-world data on upadacitinib (UPA) in patients moderate to severe Crohn’s disease (CD) are scarce. Our aim was assess long-term effectiveness and safety UPA multi-refractory Belgian patients. Methods Data from all active CD initiating between September 2022 January 2024 were retrospectively collected 17 centres. Effectiveness endpoints evaluated...
Abstract Background The anti-TNF agent infliximab (IFX) CT-P13 is now available as a subcutaneous (SC) formulation. Unanswered questions persist regarding the use of SC IFX in patients previously on optimized intravenous (IV) regimens. AMARETTO study investigates if switching to weekly 120 mg associated with better outcomes than bi-weekly dosing prior IV therapy. Methods This multicentre, randomized, open-label superiority trial includes adult IBD treated steroid-free clinical (PRO-2) and...
Abstract Background JAK inhibitors (JAKi) can induce and maintain remission in inflammatory bowel disease (IBD). Around 5% of IBD patients develop primary sclerosing cholangitis (PSC). Given the potential involvement JAK/STAT signaling PSC pathogenesis, JAKi may have a role modulating IBD-related PSC. We aim to explore course IBD-PSC on for IBD. Methods Following call-for-cases via ECCO CONFER (Round 10), we retrospectively collected baseline outcome data both IBD, before after treatment,...
Prolyl hydroxylase domain-containing proteins (PHDs) regulate the adaptation of cells to hypoxia. Pan-hydroxylase inhibition is protective in experimental colitis, which PHD1 plays a prominent role. However, it currently unknown how targeting regulates this protection and cell type(s) are involved. Here, we demonstrated that Phd1 deletion endothelial haematopoietic (Phd1f/f Tie2:cre) protected mice from dextran sulphate sodium (DSS)-induced with reduced epithelial erosions, immune...
Extra-intestinal manifestations are frequently reported in inflammatory bowel diseases. However, data comparing the effect of vedolizumab and ustekinumab on articular extra-intestinal limited. The aim here was to evaluate differences new-onset evolution pre-existing joint during both treatments.An international multicentre retrospective study performed disease patients who started or between May 2010 December 2020. were assessed at baseline evaluated throughout 2-year follow-up. Arthropathy...
Irritable bowel syndrome (IBS) is characterised by recurrent abdominal pain related to defaecation or associated with altered stool frequency consistency. Despite its prevalence, major uncertainties in the diagnostic and therapeutic management persist clinical practice.A Delphi consensus was conducted 20 experts from Belgium, consisted of literature review voting process on 78 statements. Grading recommendations, assessment, development evaluation criteria were applied evaluate quality...
Background Vedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Objective The objective this article to evaluate efficacy vedolizumab induction therapy in anti-TNF-refractory/intolerant UC CD patients real life. Methods A cohort 149 moderately severely active who failed or showed intolerance at least two TNF antagonists participated medical need program received 37 Belgian centers...